Clinical Research in Cardiology

, Volume 99, Issue 9, pp 553–556

Standard PAH therapy improves long term survival in CTEPH patients

Authors

    • Department of Respiratory MedicineUniversity of Leipzig
  • Michael Halank
    • Internal Medicine IUniversity of Dresden
  • Heinrike Wilkens
    • Universitätsklinikum Homburg/Saar
  • Hans-Joachim Schäfers
    • Universitätsklinikum Homburg/Saar
  • Ralf Ewert
    • University of Greifswald
  • Martin Riedel
    • Deutsches Herzzentrum, Klinikum Der TU München
  • Ernst Schuster
    • Institut for Medical Informatics, Statistics and EpidemiologyUniversity of Leipzig
  • Hans Pankau
    • Department of Respiratory MedicineUniversity of Leipzig
  • Stefan Hammerschmidt
    • Department of Respiratory MedicineUniversity of Leipzig
  • Hubert Wirtz
    • Department of Respiratory MedicineUniversity of Leipzig
Original Paper

DOI: 10.1007/s00392-010-0156-4

Cite this article as:
Seyfarth, H., Halank, M., Wilkens, H. et al. Clin Res Cardiol (2010) 99: 553. doi:10.1007/s00392-010-0156-4

Abstract

Background

Chronic thromboembolic pulmonary hypertension (CTEPH), subsequent to pulmonary embolism is a relatively frequent cause of pulmonary hypertension. Similar to patients with pulmonary arterial hypertension (PAH), CTEPH carries a poor prognosis. There is no hard evidence for any other therapy except pulmonary endarterectomy and none for those patients that are not eligible for this procedure.

Patients and methods

Fifty patients with confirmed, inoperable CTEPH receiving specific vasodilative therapy (prostanoids, endothelin receptor antagonists, PDE 5-inhibitors or combination) were included in this retrospective study (mean age 55 years, range 16–76 years; 36 female, 14 male). Kaplan–Meier plots of these patients were compared with Kaplan–Meier plots of two historical CTEPH patient groups without any specific vasodilative treatment by log rank tests.

Results

CTEPH patients treated with specific vasodilative compounds as used for therapy of PAH were followed up for 52 ± 30 months and had a significantly improved survival compared with patients treated without PAH type vasodilators (p ≤ 0.0002).

Conclusion

Our data may generate the hypothesis that specific vasodilative treatment improves outcome in patients with inoperable CTEPH.

Keywords

Pulmonary hypertensionPulmonary embolismSurvivalVasodilator agents

Abbreviations

CI

Cardiac index

CTEPH

Chronic thromboembolic pulmonary hypertension

IPAH

Idiopathic pulmonary arterial hypertension

mPAP

Mean pulmonary arterial pressure

PAH

Pulmonary arterial hypertension

PEA

Pulmonary endarterectomy

PVR

Pulmonary vascular resistance

Copyright information

© Springer-Verlag 2010